Posted on June 3, 2021 by Sitemaster
Earlier today, Novartis issued a media release giving the major results of the Phase III VISION trial, which compared the effectiveness of 177Lu-PSMA-617+ best standard of care (SOC), as selected by individual investigators, to SOC alone in the treatment of men with PSMA-positive men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: 177Lu-PSMA-617. VISION, castration-resistant, mCRPC, metastatic, trial | 1 Comment »
Posted on March 23, 2021 by Sitemaster
According to a media release, issued earlier today by Novartis, the company has provided preliminary data about the results of the international, multi-center, Phase III, randomized, VISION trial, which has been evaluating the efficacy and safety of lutetium-177 PSMA-617, a targeted radioligand therapy, in treatment of men with progressive, PSMA-positive, metastatic, castration-resistant prostate cancer (mCRPC) … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, lutetium-177, mCRPC, metastatic, PSMA, PSMA-617 | 3 Comments »
Posted on October 27, 2020 by Sitemaster
We hear that an investigational drug called onvansertib — a so-called polo-like kinase 1 (PLK1) inhibitor — may have benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who are showing early signs of progression on treatment with abiraterone acetate (Zytiga) + prednisone.
… READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, mCRPC, metastatic, onvansertib, Treatment, trial | 1 Comment »
Posted on October 15, 2020 by Sitemaster
So there are new, interesting data regarding the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) with sipuleucel-T (Provenge) as well as either or both of abiraterone acetate (Zytiga) and enzalutamide (Xtandi) — known generically as androgen-receptor signaling pathway inhibitors or ASPIs. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, mCRPC, metastatic, Provenge, sipuleucel-T, survival | 2 Comments »
Posted on September 21, 2020 by Sitemaster
Roche/Genentech’s investigational drug ipatasertib has demonstrated a small but statistically significant benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who had tumors exhibiting loss of the phosphatase and tensin (PTEN) homolog: a 2-month improvement in median radiographic progression-free survival (rPFS). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, ipatasertib, IPATential150, loss, metastatic, PTEN | 7 Comments »
Posted on August 26, 2020 by Sitemaster
Earlier today we reported on a recent publication based on data from the CaPSURE registry database, which stated that, among men enrolled in that database, men died sooner from their prostate cancer after they progressed to having metastatic disease over time (median survival, 2.4 years from onset of metastasis) than died from their prostate cancer if they were initially diagnosed with metastatic disease (median survival, 5.3 years). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, Diagnosis, metastatic, mortality, survival | 3 Comments »
Posted on August 23, 2020 by Sitemaster
Two clinical trials have now confirmed the abscopal or bystander effect in prostate cancer. These effects occur when cancer cells that are not directly treated are nonetheless killed. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abscopal, bystander, castration-resistant, effect, metastatic, Treatment | 1 Comment »
Posted on August 14, 2020 by Sitemaster
A company called Zenith Epigenetics has recently reported data from a Phase I/II clinical trial of a drug known as ZEN003604 or ZEN-3694 in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who have progressed on treatment with either abiraterone + prednisone or enzlautamide (Xtandi). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: castration-resistant, enzautamide, mCRPC, metastatic, ZEN-3694 | 3 Comments »
Posted on August 7, 2020 by Sitemaster
A report this week in Urologic Oncology has confirmed the importance of PSA doubling times in understanding risk for prostate cancer progression among men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: castration-resistant, doubling, mCRPC, metastasis, nmCRPC, non-metastatic, PSA, survival | 1 Comment »
Posted on June 30, 2020 by Sitemaster
Perhaps unsurprisingly, it appears to be true that “AR gain” (see below) does indeed lower overall survival (OS) and progression-free survival (PFS) rates among men with castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen, AR, ARSI, castration-resistant, CRPC, gain, inhibitor, receptor, signaling | 3 Comments »
Posted on June 26, 2020 by Sitemaster
The American Urological Association (AUA), together with the American Society for Radiation Oncology (ASTRO) and the Society for Urologic Oncology (SUO), has just issued a new set of guidelines for the management of advanced prostate cancer (see here). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, biochemical, castration-resistant, guideline, hormone-sensitive, metastatic, recurrence | 8 Comments »
Posted on June 19, 2020 by Sitemaster
According to a media release issued by Roche earlier this morning, the company’s investigational drug known as ipatasertib met one but not both of the two primary endpoints in a randomized, double-blind Phase III trial known as the IPATential150 trial. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, ipatasertib, IPATential150, mCRPC, metastatic, PTEN, Roche, trial | Leave a comment »
Posted on June 17, 2020 by Sitemaster
A newly published commentary on the CancerNetwork web site is entitled, “Radical prostatectomy as primary treatment for prostate cancer leads to better survival.” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: castration-resistant, CRPC, metastasis, outcome, radiation, surgery | 1 Comment »
Posted on May 20, 2020 by Sitemaster
Following last week’s approval of rucaparib (Rubraca), the US Food and Drug Administration (FDA) has now, also, approved the PARP inhibitor olaparib (Lynparza) for the treatment of men with with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, inhibitor, Lynparza, mCRPC, metastatic, olaparib, PARP | 1 Comment »
Posted on May 16, 2020 by Sitemaster
Yesterday evening the US Food and Drug Administration (FDA) approved rucaparib (Rubraca) for the treatment of men with BRCA1/2-mutant, metastatic, castration-resistant prostate cancer (mCRPC) who have also already been treated with androgen receptor-directed therapy and taxane-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: approval, castration-resistant, FDA, inhibitor, mCRPC, metastatic, PARP, Rubraca, rucaparib | 1 Comment »